H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $17.08, a high estimate of ...

Fintel reports that on April 11, 2025, HC Wainwright & Co. initiated coverage of Richtech Robotics (NasdaqCM:RR) with a Buy ...

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes ...

H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $32 from $29 and keeps a Buy rating on the shares. The firm says the ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy ...

HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.15).

H.C. Wainwright analyst Amit Dayal lowered the firm’s price target on ClearSign (CLIR) to $2 from $6 and keeps a Buy rating on the shares. The ...

We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to ...

On Thursday, H.C. Wainwright analyst downgraded Tempest Therapeutics (NASDAQ:TPST) stock from Buy to Neutral, despite the company's strong Phase 2 data in a study conducted by Roche. The downgrade ...

On Thursday, H.C. Wainwright affirmed a Buy rating on Endeavour Silver Corp (NYSE:EXK), a $1 billion market cap silver mining company, with a steady price target of $7.25. According to ...